| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R Kerwin, F Loft. Clozapine in the management of schizophrenia. All schizophrenic patients would benefit. BMJ (Clinical research ed.). vol 307. issue 6897. 1993-09-09. PMID:8343758. |
clozapine in the management of schizophrenia. |
1993-09-09 |
2023-08-12 |
Not clear |
| R R Owen, R Gutierrez-Esteinou, J Hsiao, K Hadd, C Benkelfat, B A Lawlor, D L Murphy, D Picka. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Archives of general psychiatry. vol 50. issue 8. 1993-08-27. PMID:8343034. |
effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. |
1993-08-27 |
2023-08-12 |
Not clear |
| H Y Meltze. New drugs for the treatment of schizophrenia. The Psychiatric clinics of North America. vol 16. issue 2. 1993-08-19. PMID:8101373. |
clozapine is a great advance in the treatment of schizophrenia. |
1993-08-19 |
2023-08-12 |
Not clear |
| H Y Meltze. New drugs for the treatment of schizophrenia. The Psychiatric clinics of North America. vol 16. issue 2. 1993-08-19. PMID:8101373. |
if progress is made in controlling its agranulocytosis, clozapine could be the drug of choice for all types of schizophrenia and perhaps other conditions as well for which neuroleptic drugs are employed, e.g., mania resistant to mood stabilizers. |
1993-08-19 |
2023-08-12 |
Not clear |
| P J Spector, L A Ople. Schizophrenia and clozapine treatment. The American journal of psychiatry. vol 150. issue 8. 1993-08-12. PMID:8328576. |
schizophrenia and clozapine treatment. |
1993-08-12 |
2023-08-12 |
Not clear |
| S R Hirsch, B K Pur. Clozapine: progress in treating refractory schizophrenia. BMJ (Clinical research ed.). vol 306. issue 6890. 1993-07-29. PMID:8518636. |
clozapine: progress in treating refractory schizophrenia. |
1993-07-29 |
2023-08-12 |
Not clear |
| J M Alvir, J A Lieberman, A Z Safferman, J L Schwimmer, J A Schaa. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. The New England journal of medicine. vol 329. issue 3. 1993-07-22. PMID:8515788. |
clozapine is an atypical antipsychotic agent that is more effective than standard neuroleptic drugs in the treatment of patients with refractory schizophrenia. |
1993-07-22 |
2023-08-12 |
Not clear |
| M Laune. Clozapine, cognition, and schizophrenia. The British journal of psychiatry : the journal of mental science. vol 162. 1993-06-03. PMID:8481757. |
clozapine, cognition, and schizophrenia. |
1993-06-03 |
2023-08-12 |
Not clear |
| D Jonsson, N Zethraeus, M Mansfield, J Wålinde. [Clozapine treatment of patients with schizophrenia. Great improvements with regard to symptoms and social life]. Lakartidningen. vol 90. issue 16. 1993-06-03. PMID:8483355. |
[clozapine treatment of patients with schizophrenia. |
1993-06-03 |
2023-08-12 |
Not clear |
| M Davidson, R S Kahn, R G Stern, J Hirschowitz, S Apter, P Knott, K L Davi. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry research. vol 46. issue 2. 1993-06-03. PMID:8483974. |
treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. |
1993-06-03 |
2023-08-12 |
Not clear |
| M Davidson, R S Kahn, R G Stern, J Hirschowitz, S Apter, P Knott, K L Davi. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry research. vol 46. issue 2. 1993-06-03. PMID:8483974. |
these findings suggest that clozapine's effect on da turnover is small and that clozapine may be effective in treatment-refractory schizophrenia by mechanisms other than, or in addition to, dopamine receptor blockade. |
1993-06-03 |
2023-08-12 |
Not clear |
| M W Jann, S R Grimsley, E C Gray, W H Chan. Pharmacokinetics and pharmacodynamics of clozapine. Clinical pharmacokinetics. vol 24. issue 2. 1993-04-16. PMID:8453823. |
the introduction of clozapine has given clinicians a unique agent for treating patients with schizophrenia that is refractory to other neuroleptics. |
1993-04-16 |
2023-08-12 |
Not clear |
| M W Jann, S R Grimsley, E C Gray, W H Chan. Pharmacokinetics and pharmacodynamics of clozapine. Clinical pharmacokinetics. vol 24. issue 2. 1993-04-16. PMID:8453823. |
only a few studies have examined the pharmacokinetics of clozapine in patients with schizophrenia. |
1993-04-16 |
2023-08-12 |
Not clear |
| M W Jann, S R Grimsley, E C Gray, W H Chan. Pharmacokinetics and pharmacodynamics of clozapine. Clinical pharmacokinetics. vol 24. issue 2. 1993-04-16. PMID:8453823. |
careful patient selection and monitoring are required when clozapine therapy is used in patients with schizophrenia. |
1993-04-16 |
2023-08-12 |
Not clear |
| N R Swerdlow, M A Geye. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacology, biochemistry, and behavior. vol 44. issue 3. 1993-04-12. PMID:8451276. |
clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. |
1993-04-12 |
2023-08-12 |
rat |
| M Laune. Clozapine. British journal of hospital medicine. vol 49. issue 1. 1993-03-17. PMID:8431727. |
clozapine is an atypical agent for intractable schizophrenia which was introduced into the uk at the beginning of 1990. |
1993-03-17 |
2023-08-12 |
Not clear |
| B Blanz, M H Schmid. Clozapine for schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry. vol 32. issue 1. 1993-03-10. PMID:8428878. |
clozapine for schizophrenia. |
1993-03-10 |
2023-08-12 |
Not clear |
| L M Davies, M F Drummon. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. The British journal of psychiatry : the journal of mental science. vol 162. 1993-02-26. PMID:8425137. |
an analysis was conducted on the basis of available data to assess the economic consequences of clozapine therapy for people with moderate to severe schizophrenia in long-stay institutions or staffed group homes, with a view to providing an estimate of the likely costs and benefits of the drug. |
1993-02-26 |
2023-08-12 |
Not clear |
| L M Davies, M F Drummon. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. The British journal of psychiatry : the journal of mental science. vol 162. 1993-02-26. PMID:8425137. |
a prospective health economic study with clozapine in the management of schizophrenia would be desirable to confirm these results. |
1993-02-26 |
2023-08-12 |
Not clear |
| T E Goldberg, R D Greenberg, S J Griffin, J M Gold, J E Kleinman, D Pickar, S C Schulz, D R Weinberge. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. The British journal of psychiatry : the journal of mental science. vol 162. 1993-02-26. PMID:8425138. |
the effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. |
1993-02-26 |
2023-08-12 |
Not clear |